Top

Quality of Life Research

Published in:

01-06-2013 | Review

The impact of second-line agents on patients’ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review

Authors: Arijit Ganguli, Phillip Wiegand, Xin Gao, John A. Carter, Marc F. Botteman, Saurabh Ray

Published in: Quality of Life Research | Issue 5/2013

Abstract

Purpose

In advanced non-small cell lung cancer (NSCLC), progressive disease burdens patients considerably. Second-line (2L) chemotherapy improves survival marginally but humanistic outcomes (i.e., quality of life, QOL) are underreported. The impact of 2L therapy remains an important consideration for patients and caregivers, and there have been QOL reviews for 1L, but not 2L, therapies. This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC.

Methods

Clinical trial reports of approved, guideline-supported 2L or maintenance therapy for NSCLC published from 2000 to 2010 were identified from PubMed/Medline and clinical meetings. Outcomes were stratified by overall QOL impact, domain/symptom-specific effects, effect over time, and subgroup effects.

Results

Of 145 studies identified, 24 full-text articles were retained. Studies with docetaxel versus best supportive care (n = 1) and active comparators (n = 4) reported non-significant overall QOL improvements, as did studies of gefitinib versus placebo and active comparator (n = 7). Overall QOL improvements were seen for gefitinib versus docetaxel (n = 2) and gefitinib in a single-arm study (n = 1). At the symptom level, studies of docetaxel (n = 4/7), gefitinib (n = 7/9), and pemetrexed (n = 1) reported non-significant results. Subgroup analyses indicated improved QOL outcomes for gefitinib-treated responders versus non-responders, worse QOL for gefitinib-treated smokers versus placebo, worse QOL for gefitinib-treated Asian patients versus placebo, and longer time to symptom deterioration in erlotinib versus placebo-treated elderly patients.

Conclusions

Significant improvements in overall QOL with 2L chemotherapy for advanced NSCLC were infrequent. Single-arm studies and those with less toxic regimens more commonly provided statistically significant improvements in QOL outcomes. Methodological heterogeneity impedes cross-study QOL comparisons.

Wisnivesky, J. P., Yankelevitz, D., & Henschke, C. I. (2005). Stage of lung cancer in relation to its size: Part 2. Evidence. Chest, 127(4), 1136–1139.PubMedCrossRef

Azzoli, C. G., Temin, S., Aliff, T., Baker, S., Jr, Brahmer, J., Johnson, D. H., et al. (2011). 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 29(28), 3825–3831.PubMedCrossRef

NCCN Guidelines Panel. (2012). NCCN Clinical practice guidelines in oncology: Non small cell lung cancer: Version 3.2012.

Goffin, J., Lacchetti, C., Ellis, P. M., Ung, Y. C., & Evans, W. K. (2010). First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. Journal of Thoracic Oncology, 5(2), 260–274.PubMedCrossRef

Stinchcombe, T. E., & Socinski, M. A. (2008). Considerations for second-line therapy of non-small cell lung cancer. Oncologist, 13(Suppl), 128–136.

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346(2), 92–98.PubMedCrossRef

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542–2550.PubMedCrossRef

Socinski, M. A., Schell, M. J., Peterman, A., Bakri, K., Yates, S., Gitten, R., et al. (2002). Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. Journal of Clinical Oncology, 20(5), 1335–1343.PubMedCrossRef

Passaro, A., Cortesi, E., & De, M. F. (2011). Second-line treatment of non-small-cell lung cancer: Chemotherapy or tyrosine kinase inhibitors? Expert Review of Anticancer Therapy, 11(10), 1587–1597.PubMedCrossRef

10.

Maione, P., Rossi, A., Bareschino, M. A., Sacco, P. C., Schettino, C., Falanga, M., et al. (2011). Factors driving the choice of the best second-line treatment of advanced NSCLC. Reviews on Recent Clinical Trials, 6(1), 44–51.PubMedCrossRef

11.

Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., et al. (2005). TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 23(25), 5892–5899.PubMedCrossRef

12.

Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De, M. F., Von Pawel, J., et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology, 22(9), 1589–1597.PubMedCrossRef

13.

Fossella, F., Pereira, J. R., Pawel von, P. J., Pluzanska, A., Gorbounova, V., Kaukel, E., et al. (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. Journal of Clinical Oncology, 21(16), 3016–3024.PubMedCrossRef

14.

Moro-Sibilot, D., Vergnenegre, A., Smit, E. F., Toy, E., Parente, B., Schmitz, S., et al. (2010). Second-line therapy for NSCLC in clinical practice: Baseline results of the European SELECTION observational study. Current Medical Research and Opinion, 26(11), 2661–2672.PubMedCrossRef

15.

Silvestri, G., Pritchard, R., & Welch, H. G. (1998). Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ, 317(7161), 771–775.PubMedCrossRef

16.

Dancey, J., Shepherd, F. A., Gralla, R. J., & Kim, Y. S. (2004). Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer, 43(2), 183–194.PubMedCrossRef

17.

Gebbia, V., Gridelli, C., Verusio, C., Frontini, L., Aitini, E., Daniele, B., et al. (2009). Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer, 63(2), 251–258.PubMedCrossRef

18.

Bezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., et al. (2006). Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 24(24), 3831–3837.PubMedCrossRef

19.

Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y. L., et al. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet, 372(9652), 1809–1818.PubMedCrossRef

20.

Tanvetyanon, T., Soares, H. P., Djulbegovic, B., Jacobsen, P. B., & Bepler, G. (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2(12), 1091–1097.PubMedCrossRef

21.

D’Addario, G., Fruh, M., Reck, M., Baumann, P., Klepetko, W., & Felip, E. (2010). Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Suppl 5), v116–v119.PubMedCrossRef

22.

Gridelli, C., Maione, P., Rossi, A., Ferrara, M. L., Bareschino, M. A., Schettino, C., et al. (2009). Potential treatment options after first-line chemotherapy for advanced NSCLC: Maintenance treatment or early second-line? Oncologist, 14(2), 137–147.PubMedCrossRef

23.

Committee For Medicinal Products For Human Use. (2005). Reflection Paper On The Regulatory Guidance For The Use Of Healthrelated Quality Of Life (Hrql) Measures In The Evaluation Of Medicinal Products.25.

24.

US Department of Health and Human Services. (2009). Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.43.

25.

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery, 8(5), 336–341.PubMedCrossRef

26.

National Institutes of Health (2012). ClinicalTrials.gov.

27.

Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D’haese, S., et al. (2003). Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials–does HRQOL evaluation in prostate cancer research inform clinical decision making? Journal of Clinical Oncology, 21(18), 3502–3511.PubMedCrossRef

28.

US Food an Drug Administration (2003). Workshop summary on endpoints for approval of cancer drugs for lung cancer.

29.

Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., et al. (2009). Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 27(4), 591–598.PubMedCrossRef

30.

Gridelli, C., Gallo, C., Di, M. M., Barletta, E., Illiano, A., Maione, P., et al. (2004). A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer, 91(12), 1996–2004.PubMedCrossRef

31.

Krzakowski, M., Ramlau, R., Jassem, J., Szczesna, A., Zatloukal, P., Von Pawel, J., et al. (2010). Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. Journal of Clinical Oncology, 28(13), 2167–2173.PubMedCrossRef

32.

Lai, C. L., Tsai, C. M., Chiu, C. H., Wang, G. S., Su, W. J., Chen, Y. M., et al. (2005). Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology, 35(12), 700–706.PubMedCrossRef

33.

Park, J. O., Kim, S. W., Ahn, J. S., Suh, C., Lee, J. S., Jang, J. S., et al. (2007). Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. Journal of Clinical Oncology, 25(33), 5233–5239.PubMedCrossRef

34.

Paz-Ares, L., Ross, H., O’Brien, M., Riviere, A., Gatzemeier, U., von Pawel, J., et al. (2008). Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer, 98(10), 1608–1613.PubMedCrossRef

35.

Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., & Shepherd, F. A. (2008). Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 26(14), 2350–2357.PubMedCrossRef

36.

Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczesna, A., Juhasz, E., et al. (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology, 11(6), 521–529.PubMedCrossRef

37.

Perez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., et al. (2004). Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. Journal of Clinical Oncology, 22(16), 3238–3247.PubMedCrossRef

38.

Cella, D., Herbst, R. S., Lynch, T. J., Prager, D., Belani, C. P., Schiller, J. H., et al. (2005). Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of Clinical Oncology, 23(13), 2946–2954.PubMedCrossRef

39.

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Journal of Clinical Oncology, 21(12), 2237–2246.PubMedCrossRef

40.

Gelibter, A., Ceribelli, A., Pollera, C. F., Milella, M., Moscetti, L., Sperduti, I., et al. (2005). Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer. Journal of Cancer Research Clinical Oncology, 131(12), 783–788.CrossRef

41.

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, T. J., Jr., Prager, D., Belani, C. P., et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 290(16), 2149–2158.PubMedCrossRef

42.

Lee, D. H., Park, K., Kim, J. H., Lee, J. S., Shin, S. W., Kang, J. H., et al. (2010). Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clinical Cancer Research, 16(4), 1307–1314.PubMedCrossRef

43.

Mu, X. L., Li, L. Y., Zhang, X. T., Wang, S. L., & Wang, M. Z. (2004). Evaluation of safety and efficacy of gefitinib (‘iressa’, zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: Experience from a compassionate-use programme. BMC Cancer, 4, 51.PubMedCrossRef

44.

Sekine, I., Ichinose, Y., Nishiwaki, Y., Yamamoto, N., Tsuboi, M., Nakagawa, K., et al. (2009). Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: Results of a randomized phase III study (V-15–32) of gefitinib versus docetaxel. Annals of Oncology, 20(9), 1483–1488.PubMedCrossRef

45.

Takeda, K., Hida, T., Sato, T., Ando, M., Seto, T., Satouchi, M., et al. (2010). Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a west Japan thoracic oncology group trial (WJTOG0203). Journal of Clinical Oncology, 28(5), 753–760.PubMedCrossRef

46.

Thatcher, N., Chang, A., Parikh, P., Rodrigues, P. J., Ciuleanu, T., von Pawel, J., et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366(9496), 1527–1537.PubMedCrossRef

47.

Cufer, T., Vrdoljak, E., Gaafar, R., Erensoy, I., & Pemberton, K. (2006). Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs, 17(4), 401–409.PubMedCrossRef

48.

De, M. F., Pereira, J. R., Fossella, F., Perry, M. C., Reck, M., Salzberg, M., et al. (2008). Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: An analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. Journal of Thoracic Oncology, 3(1), 30–36.CrossRef

49.

Plunkett, T. A., Chrystal, K. F., & Harper, P. G. (2003). Quality of life and the treatment of advanced lung cancer. Clinical Lung Cancer, 5(1), 28–32.PubMedCrossRef

50.

Oort, F. J., Visser, M. R., & Sprangers, M. A. (2009). Formal definitions of measurement bias and explanation bias clarify measurement and conceptual perspectives on response shift. Journal of Clinical Epidemiology, 62(11), 1126–1137.PubMedCrossRef

Title: The impact of second-line agents on patients’ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review
Authors: Arijit Ganguli
Phillip Wiegand
Xin Gao
John A. Carter
Marc F. Botteman
Saurabh Ray
Publication date: 01-06-2013
Publisher: Springer Netherlands
Published in: Quality of Life Research / Issue 5/2013
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-012-0229-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The impact of second-line agents on patients’ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2013

Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being

The Hearing Handicap Inventory for Elderly-Screening (HHIE-S) versus a single question: reliability, validity, and relations with quality of life measures in the elderly community, Japan

Favorable effects of explanatory illustrations attached to a self-administered questionnaire for upper extremity disorders

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients

An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences

Visual analogue scales: scale recalibration by patients with dementia and their proxies